1035374-46-9

Upstream product

• 1035374-45-8 4-((2S)-4-((1R)-1-phenylethyl)morpholin-2-yl)benzaldehyde 
• 879205-74-0 (2S)-2-(4-bromophenyl)-4-[(1R)-1-phenylethyl]morpholine 

Downstream Products

• 1035374-47-0 4-((2S)-morpholin-2-yl)benzonitrile hydrochloride 
• 1245652-72-5 N'-hydroxy-4-((S)-4-((R)-1-phenylethyl)morpholine-2-yl)benzamidine 

Relevant academic research and scientific papers

Practical and scalable synthesis of a benzonitrile derivative via palladium-catalyzed cyanation with potassium ferrocyanide

A practical and reproducible synthetic method for the preparation of a benzonitrile derivative (1) from an aryl bromide (2) via Pd-catalyzed cyanation was established with dimethylacetamide (DMAc)-toluene as a mixed solvent. Optimization was examined by a design of experiments (DoE) technique to enhance reaction conversion and reduce the dimeric impurity 3, and desired benzonitrile derivative 1 was successfully obtained in high yields with excellent quality control on a 117 kg scale.

INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF

A production method of an optically active 2-{4-(5-substituted-oxadiazolyl) phenyl}morpholine which is useful as an intermediate for synthesizing a pharmaceutical agent is provided and the method comprises the following steps 1) to 4): 1) reacting a bromo

6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g.

2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein each R1 represents hydrogen atom or the like; X represents oxygen atom or the like; A represents a C3